Diaxonhit is informed by Allergan that Bristol-Myers Squibb has decided to
stop development of EHT/AGN 0001
PARIS -- February 6, 2013
Diaxonhit (Paris:ALEHT), the new leading French provider of specialty
diagnostic solutions, was notified of the decision by Bristol-Myers Squibb
(BMS) not to continue further development of EHT/AGN 0001, a compound for the
treatment of neuropathic pain, and to return to Allergan this program derived
from its collaboration with Diaxonhit. The reasons for this decision were not
communicated to Diaxonhit.
Diaxonhit would like to emphasize that this peripheral event has no impact on
the group's fundamentals; in particular it will not impact its recurring
revenues and its main activities in diagnostics.
This outcome, inherent in the development of therapeutics, has no effect on
Diaxonhit’s long lasting scientific collaboration with Allergan, including
current development projects underway.
"This case confirms altogether the relevance of our strategy for creating a
new French integrated leader in the in-vitro diagnostics field, with strong
development potential as well as diversified activities and revenue sources,"
said Loïc Maurel, CEO of Diaxonhit.
Diaxonhit (NYSE Alternext, FR0004054427, ALEHT) is a French fully integrated
leader in the in-vitro diagnostic field, involved from research to
commercialization of specialty diagnostic products.
With many partnerships and a strong presence in hospitals, Diaxonhit has an
extensive commercialization network. Through its affiliate, InGen, it
commercializes and services, mostly under exclusivity agreements, in-vitro
diagnostic kits and advanced equipment. It operates mainly in the fields of
transplantation, infectious diseases and autoimmunity, product quality control
and rapid tests, including Tetanus Quick Stick ®, a proprietary product.
The group also owns a diversified portfolio of products in development,
including both innovative molecular and non-molecular diagnostics, covering
three main specialty areas: immuno-infection, Alzheimer's disease and cancer.
Diaxonhit headquarters are located in Paris and its affiliate in the Paris
region. The Group is listed on NYSE Alternext in Paris and is part of the NYSE
Alternext OSEO innovation index.
For more information, please visit: http://www.diaxonhit.com.
This press release contains elements that are not historical facts including,
without limitation, certain statements about future expectations and other
forward-looking statements. Such statements are based on management’s current
views and assumptions and involve known and unknown risks and uncertainties
that could cause actual results, performance or events to differ materially
from those anticipated.
In addition, Exonhit, its shareholders, and its affiliates, directors,
officers, advisors and employees have not verified the accuracy of, and make
no representations or warranties in relation to, statistical data or
predictions contained in this press release that were taken or derived from
third party sources or industry publications, and such statistical data and
predictions are used in this press release for information purposes only.
Finally, this press release may be drafted in the French and English
languages. In an event of differences between the texts, the French language
version shall prevail.
Hervé Duchesne de Lamotte, +33 1 53 94 52 49
+ 33 1 56 88 11 11
Press spacebar to pause and continue. Press esc to stop.